Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jon Henry

Vascular Surgery Columbus, OH Medical Doctor

NPI 1689833360 CMS profile 2788549

285 E State St Ste 260, Columbus, OH 43215

Open in the dashboard

General payments

$8,737

157 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jon Henry of Columbus, OH is reported in the CMS Open Payments database as having received $8,737 across 157 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $599 13
2024 General $1,037 29
2023 General $1,251 21
2022 General $2,192 35
2021 General $661 18
2020 General $212 10
2019 General $2,785 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jon Henry
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Jon Henry were reported at $599. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Jon Henry Vascular Surgery median Middle half National median
2019 $2,785 $796 $226–$2,363 $163
2020 $212 $348 $118–$1,110 $114
2021 $661 $471 $158–$1,421 $132
2022 $2,192 $725 $222–$2,183 $149
2023 $1,251 $836 $257–$2,440 $160
2024 $1,037 $909 $252–$2,619 $164
2025 $599 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,833 36 payments
  2. Boston Scientific Corporation $2,178 64 payments
  3. Silk Road Medical, Inc. $1,251 10 payments
  4. Medtronic, Inc. $720 11 payments
  5. Abbott Laboratories $380 4 payments
  6. Shockwave Medical, Inc $283 4 payments
  7. Philips Electronics North America Corporation $252 10 payments
  8. Bard Peripheral Vascular, Inc. $171 4 payments
  9. Bolton Medical Inc $149 1 payment
  10. Teleflex LLC $142 1 payment
  11. Other $377 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,748 138 payments
  2. Travel and Lodging $2,943 18 payments
  3. Education $46 1 payment
Products named General payments · program years 2019–2025
  1. GORE TAG Thoracic Endoprosthesis $1,277 8 payments
  2. ENROUTE 0.014 Guidewire $1,233 9 payments
  3. ENROUTE Transcarotid Stent System $1,233 9 payments
  4. ENROUTE Transcarotid Neuroprotection System $1,233 9 payments
  5. ENHANCE Transcarotid Peripheral Access Kit $1,233 9 payments
  6. General Therapies $851 6 payments
  7. ENDURANT IIS $348 3 payments
  8. GORE VIABAHN Endoprosthesis with Heparin $335 3 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $283 4 payments
  10. EXCLUDER Conformable AAA Endoprosthesis with Active Control $272 3 payments
  11. Other $3,910 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

166

Median for General Surgery: 59

Drug cost

$25,136

Median for General Surgery: $393

Branded share of claims

64.5%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $24,153
Cilostazol Generic 35 $501
Clopidogrel Clopidogrel Bisulfate Brand 83 $406
Atorvastatin Calcium Generic 24 $76

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$38,582

Medicare's payments for the services billed

Medicare patients

506

Average age 74

Services billed

776

273 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 52%
Diabetes 47%
Chronic kidney disease 42%
Depression 36%
Heart failure 35%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record